Payment overview · 2025
General Payments
$221.63
11 reported records · 5 companies
Healthcare provider profile · identity verified
Blake E Milner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EASTMAN, GA · NPI 1336256015
Verified facts
What the public records show
CMS Open Payments records show Blake E Milner, M.D. received $221.63 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ingrezza, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.48 | 34.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.90 | 27.5% | 4 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $50.20 | 22.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.08 | 9.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.97 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.63 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.48 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.90 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.88 | 3 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $50.20 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 163 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
172 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
163 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1315 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 925 | 184 |
| Losartan Potassium | Losartan Potassium | 817 | 165 |
| Potassium Chloride | Potassium Chloride | 778 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 143 |
| Gabapentin | Gabapentin | 735 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 682 | 143 |
| Lisinopril | Lisinopril | 620 | 131 |
| Eliquis | Apixaban | 611 | 81 |
| Furosemide | Furosemide | 533 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 519 | 112 |
| Clopidogrel | Clopidogrel Bisulfate | 450 | 87 |
| Omeprazole | Omeprazole | 443 | 94 |
| Sertraline Hcl | Sertraline Hcl | 396 | 71 |
| Famotidine | Famotidine | 383 | 90 |
| Trazodone Hcl | Trazodone Hcl | 373 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 351 | 71 |
| Januvia | Sitagliptin Phosphate | 346 | 49 |
| Meloxicam | Meloxicam | 336 | 82 |
| Metformin Hcl Er | Metformin Hcl | 327 | 71 |
| Tramadol Hcl | Tramadol Hcl | 327 | 85 |
| Simvastatin | Simvastatin | 321 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 313 | 56 |
| Donepezil Hcl | Donepezil Hcl | 282 | 44 |
| Carvedilol | Carvedilol | 258 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 254 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 58 |
| Allopurinol | Allopurinol | 233 | 41 |
| Metformin Hcl | Metformin Hcl | 229 | 57 |
| Mirtazapine | Mirtazapine | 216 | 38 |
| Montelukast Sodium | Montelukast Sodium | 214 | 48 |
| Jardiance | Empagliflozin | 211 | 31 |
| Memantine Hcl | Memantine Hcl | 208 | 27 |
| Tradjenta | Linagliptin | 195 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 180 | 31 |
| Ozempic | Semaglutide | 178 | 38 |
| Levetiracetam | Levetiracetam | 175 | 21 |
| Mounjaro | Tirzepatide | 172 | 27 |
| Ezetimibe | Ezetimibe | 164 | 36 |
| Divalproex Sodium | Divalproex Sodium | 163 | 20 |
| Gemtesa | Vibegron | 163 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 34 |
| Celecoxib | Celecoxib | 153 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 148 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 38 |
| Valsartan | Valsartan | 138 | 27 |
| Pregabalin | Pregabalin | 136 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 132 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 130 | 27 |
| Sucralfate | Sucralfate | 130 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 19 |
| Spironolactone | Spironolactone | 120 | 20 |
| Atenolol | Atenolol | 112 | 23 |
| Buspirone Hcl | Buspirone Hcl | 109 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 21 |
| Linzess | Linaclotide | 104 | 20 |
| Nifedipine Er | Nifedipine | 103 | 22 |
| Xarelto | Rivaroxaban | 102 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 31 |
| Glimepiride | Glimepiride | 94 | 27 |
| Alendronate Sodium | Alendronate Sodium | 90 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 19 |
| Lorazepam | Lorazepam | 82 | 27 |
| Prednisone | Prednisone | 82 | 54 |
| Farxiga | Dapagliflozin Propanediol | 80 | 11 |
| Finasteride | Finasteride | 77 | 12 |
| Myrbetriq | Mirabegron | 74 | 12 |
| Cilostazol | Cilostazol | 68 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 68 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 39 |
| Desloratadine | Desloratadine | 67 | 23 |
| Belsomra | Suvorexant | 66 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 30 |
| Entresto | Sacubitril/Valsartan | 65 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 64 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 54 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 21 |
| Novolog | Insulin Aspart | 51 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 12 |
| Ibuprofen | Ibuprofen | 48 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 15 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 11 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 42 | suppressed |
| Eszopiclone | Eszopiclone | 41 | 15 |
| Letrozole | Letrozole | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 17 |
| Klor-Con M20 | Potassium Chloride | 40 | 15 |
| Brilinta | Ticagrelor | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 33 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 11 |
| Fluconazole | Fluconazole | 36 | 22 |
| Methylprednisolone | Methylprednisolone | 36 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Colesevelam Hcl | Colesevelam Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Ramipril | Ramipril | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Insulin Aspart | Insulin Aspart | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Sotalol | Sotalol Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | 12 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Admelog | Insulin Lispro | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 20 |
| Topiramate | Topiramate | 24 | suppressed |
| Colchicine | Colchicine | 23 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Daptomycin | Daptomycin | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Enulose | Lactulose | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Pindolol | Pindolol | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.63 · 11 records | Lilly USA, LLC | APLIGRAF, GEMTESA, INGREZZA, MOUNJARO, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error